Intellia Therapeutics

Pioneer in CRISPR/Cas9-based gene editing therapeutics, developing in vivo and ex vivo treatments for genetic diseases, cancer, and autoimmune conditions. Publicly traded on NASDAQ (NTLA).

Location
Cambridge, Massachusetts, USA
Founded
2014
Investors
1
Categories
therapeutics, biotech, gene-editing, crispr, public

Investors

NameLocationTypeStagesPortfolio
Atlas VentureCambridge, USAbiotech-focused
seedseries-a+1
1